StockWireNews

Low Float (GTHR) Has Now Gone Parabolic, Up Approximately 441% And Could Just Be Getting Started

August 2nd

Good Morning,

GTHR continues its early breakout move.

Up approximately 441% now, GTHR could still be gaining steam as it has already hit a high of $.12.

Remember, this profile has a 52-week high of $.47 when it exploded back in April during a single day.

And, another key thing to make a note of is this profile's low float. According to the OTC Markets website, GTHR has a float of 6.2Mn shares.

With today's early move, GTHR is now trading above several key lines including its:

• 5-Day Simple Moving Average (SMA)
• 20-Day SMA
• 50-Day SMA
• 100-Day SMA
• 200-Day SMA
• 5-Day Exponential Moving Average (EMA)
• 13-Day EMA

Take a moment now and read the complete GTHR report below and get this profile on your radar quickly.

----

The opening bell just went off so we need to dive in quick.

I've got a new profile to bring to your attention this morning and you need to get it on your radar quickly.

For today, biotech company GeneThera, Inc. (GTHR) requires immediate attention. Here's why...

Back in June, I brought you another biotech profile in (JAN).

Let me tell you, that bad boy rocketed like a missile.

Surging approximately $4.00+ in the blinking of an eye from June 21st to the 22nd, JAN quickly became the talk of the town.

But, Why Was It Capable Of That Surge?

One major reason: a low float.

And, just like that breakout star, GTHR also has a low float.

According to the OTCMarkets website, GTHR has a float of approximately 6.2Mn shares.

With low floats like this, profiles can be susceptible to potential volatility. Volatility can lead to quick moves up the charts just like we saw in JAN two months ago.

And you know what, this profile has demonstrated huge breakout potential. Look no further than April 6th of 2021. Check it out:

On 4/6, GTHR exploded for a crazy surge of 1,466% intraday after opening at $.03 and running to a high of $.47.

Now, I'm not saying that same type of run is going to happen again today, but you need to be aware of this profile's potential upside.

So Why Pay Attention To GTHR Now?

The company has been hard at work over the past several months attempting to combat the current health crisis in their own way. Check it out:

GeneThera Inc. Expands Its Operation in the United Kingdom

- Dr. Tony Milici, Chairman and CEO of GeneThera Inc., commented: “We have decided to expand our operation to the UK because we see great opportunities both at the government and private sector level. The UK has been at forefront of the CV-19 pandemic. The B.1.1.7 SARS CoV-2 British variant has proven to be of particular importance with an estimated transmission rate between forty to eighty percent more transmissible than the wild-type SCV-2 virus. Cases of B.1.1.7 variant are most likely to be under reported, if reported at all, as common tests are not able to differentiate this variant from other SCV-2 variants. We believe that our technology platform can significantly help in the detection of this variant by testing wastewater samples."

-----

GeneThera enters into a collaboration agreement with an International Construction Advisor Company to build a network of zoonotic diseases laboratory facilities

Dr. Tony Milici, Chairman and CEO of GeneThera, Inc. stated; “We are extremely thrilled to partner with Cumming. This is a gigantic step forward for the realization of GeneThera’s Zoonotic Diseases Alert Shield System (ZIDAS) and its related technology. Thanks to the expertise and support of Cumming, we will be able to implement and expand our business model and technology platform more quickly and efficiently. Our laboratory facility in Colorado will be the first step for the creation and implementation of the ZIDAS platform both nationally and internationally. Cumming expertise and knowledge in laboratory design will provide GeneThera with the necessary tools to achieve its goal of creating a network of labs dedicated to diagnostic and therapeutic of zoonotic diseases using standardized state-of-the-art technology. As previously stated, technology standardization is absolutely vital to successfully predict control and treat pandemics. One of the lessons we must learn from the CV-19 pandemic is that without standardized laboratory protocols and facilities, we will never be able to successfully be ahead of pandemic-causing viruses now and in the future.”

-----

GeneThera’s Strategy for the Development of a Global Zoonotic Diseases Surveillance System Using Smart Testing Technology

Dr. Tony Milici, Chairman & CEO of GeneThera, commented: “We believe that the implementation of SMART TESTING TECHNOLOGY (STT) could change the course of the CV pandemic and predict future pandemic before they developed. It is quite clear that performing massive number of testing using unreliable or non standardized technology does not control the virus or provide scientists the information needed to understand the spread of the virus and the insurgence of new potentially dangerous strains. It is still unclear whether or not vaccines will be able to stop the CV."

-----

More About The Company - GeneThera, Inc. (GTHR)

GeneThera is a biotechnology company developing molecular robotic/AI diagnostics and therapeutics in an effort to control and eradicate zoonotic diseases. GeneThera developed molecular assays for BSE and Mycobacterium Avium Paratuberculosis (MAP). MAP is an infectious organism causing Paratuberculosis in dairy cows that is also linked to Crohn’s Disease in humans. The company utilizes these technologies to minimize the spread of animal infectious organisms. Management and prevention of zoonotic diseases is crucial to human and animal health on a global scale.

Company Website

-----

Coverage is officially initiated on GTHR. When you have time later, do this:

If there are any more updates today, I'll get them out to you quickly.

Sincerely,

Kai Parker

StockWireNews

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)